Important risks and uncertainties are set forth in our Form 10-Q that was filed on November ... SALT 50 to SALT 100 for at least six months in order to be eligible for inclusion.

Important risks and uncertainties are set forth in our Form 10-Q that was filed on November ... SALT 50 to SALT 100 for at least six months in order to be eligible for inclusion.

The rise in chronic illnesses like infections, autoimmune diseases, and various forms of cancer worldwide ... stocks were then ranked in ascending order based on the number of hedge fund holders ...

Sanofi stock forms a Golden Cross, signaling bullish momentum as Dupixent nears FDA approval for bullous pemphigoid. SNY’s technicals remain strong, with all key moving averages trending higher ...

Dupixent (dupilumab) is a brand-name subcutaneous injection that’s prescribed for atopic dermatitis, asthma, and more. It works to treat those conditions by blocking proteins that cause ...

Regeneron (REGN) and Sanofi (SNY) announced that the Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing ...

The trial evaluated Dupixent added to background maximal standard-of-care ... Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also ...

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly ...

After several months, inflammatory disease medication Dupixent has finally reclaimed its spot atop the rankings for over-the-counter (OTC) and Rx brand marketing on TV. The Regeneron and Sanofi brand, ...

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in ...